---
title: "New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297835264.md"
description: "Revolution Medicines (RVMD) announced that The New England Journal of Medicine published Phase 1/2 clinical data on RASONQUE™ (daraxonrasib). This oral RAS(ON) inhibitor was evaluated in patients with advanced, previously treated RAS mutant non-small cell lung cancer. The report details trial findings aimed at providing innovative treatment solutions for RAS-addicted cancers."
datetime: "2026-09-02T21:52:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297835264.md)
  - [en](https://longbridge.com/en/news/297835264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297835264.md)
generator: "portal-rs"
---

# New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines, Inc., a leading oncology company listed on Nasdaq as RVMD, based in Redwood City, California, disclosed in a recent announcement that The New England Journal of Medicine has released a report detailing findings from a Phase 1/2 clinical study of their medication RASONQUE (daraxonrasib). This drug, an oral inhibitor targeting RAS(ON), was evaluated in patients with advanced RAS mutant non-small cell lung cancer (NSCLC) who had undergone prior treatments. The report provides insights from the trial conducted, aiming to offer innovative treatment solutions for patients battling RAS-addicted cancers.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative?](https://longbridge.com/en/news/298213245.md)
- [Revolution Medicines Got Its Breakthrough—What Moves It Next?](https://longbridge.com/en/news/298062833.md)
- [Revolution Medicines, Inc. $RVMD Shares Sold by Jasper Ridge Partners L.P.](https://longbridge.com/en/news/297423774.md)
- [Akeso, Summit cancer drug confirms lung cancer survival benefit](https://longbridge.com/en/news/298059867.md)
- [These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts](https://longbridge.com/en/news/298130385.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**